NASDAQ:TENX Tenax Therapeutics Q4 2024 Earnings Report $7.46 +0.05 (+0.61%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tenax Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS -$0.52Beat/MissBeat by +$0.34One Year Ago EPSN/ATenax Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenax Therapeutics Announcement DetailsQuarterQ4 2024Date3/25/2025TimeBefore Market OpensConference Call DateTuesday, March 25, 2025Conference Call Time8:00AM ETUpcoming EarningsTenax Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual Report(10-K) Tenax Therapeutics Earnings HeadlinesTenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200-Day Moving Average - What's Next?October 11 at 3:21 AM | americanbankingnews.comTenax Therapeutics management to meet with Piper SandlerOctober 2, 2025 | msn.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.October 14 at 2:00 AM | Weiss Ratings (Ad)Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEFSeptember 16, 2025 | msn.comTenax Therapeutics Secures European Patent Protection for TNX-103 and Levosimendan Formulations Until December 2040September 16, 2025 | quiverquant.comQTenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEFSeptember 16, 2025 | globenewswire.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications. Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials. Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
